Modeling the effects of omalizumab over 5 years among patients with moderate-to-severe persistent allergic asthma.
OBJECTIVE
Omalizumab is a monoclonal antibody indicated for adults and adolescents with moderate-to-severe persistent allergic asthma whose symptoms are inadequately controlled with inhaled corticosteroids. Omalizumab has been demonstrated to improve health outcomes of asthmatic patients as compared to placebo. However, to date, the trials conducted have been relatively short (less than 1 year) and have been restricted to a limited set of patients who met the clinical study criteria. This study examined the expected effects of omalizumab over 5 years on a representative sample of all patients eligible for omalizumab in the US.


METHODS
The Archimedes Asthma Model was used to simulate the following treatment scenarios for US patients age 12 and older with moderate-to-severe persistent allergic asthma: (1) Current asthma treatment (CAT) (treatment according to National Heart, Lung, and Blood Institute (NHLBI) guidelines, without use of omalizumab, and with adherence levels as observed in the National Asthma Survey); (2) Guideline asthma treatment (GAT) without omalizumab (NHLBI guidelines without use of omalizumab, assuming perfect adherence); (3) GAT plus omalizumab; and (4) GAT plus omalizumab with steroid reduction. The simulation was run for 5 years.


METHODS
Symptom days, asthma exacerbations, emergency room/urgent care (ER/UC) visits, hospitalizations, and medication use.


RESULTS
For the full simulated population of omalizumab-eligible patients, the simulation forecasted that omalizumab would decrease cumulative exacerbations by 30%, ER/UC visits by 37%, and hospitalizations by 38% over 5 years. Among responders to omalizumab, assuming that 60.5% of patients respond, the results suggest that omalizumab would decrease cumulative exacerbations by 50%, ER/UC visits by 62%, and hospitalizations by 63% over 5 years. In addition, the simulation predicted that omalizumab would allow 45% of patients who are taking more than the minimum steroid dose to reduce their steroid dose, while maintaining similar asthma control as achieved in the GAT plus omalizumab arm (no steroid dose reduction) and better asthma control than following treatment protocols that do not include omalizumab.


CONCLUSIONS
Based on the results of this simulation, omalizumab is effective for those who respond, reducing serious events by more than 50% among the responder group, while also allowing many patients to reduce their steroid dose.
Archimedes, Inc., San Francisco, CA, USA. helene.grossman@archimedesmodel.com
H L
HL
Grossman
Amory
A
Schlender
Peter
P
Alperin
Elizabeth L
EL
Stanley
Jie
J
Zhang
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000145:classification / Q000150:complications / Q000188:drug therapy*; D002648:Child; D003198:Computer Simulation; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006967:Hypersensitivity / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D008962:Models, Theoretical; D000069444:Omalizumab; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
D018927:Anti-Asthmatic Agents; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069444:Omalizumab